Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
1. An anti-human programmed death receptor 1 (PD-1) antibody formulation, comprising:
a) about 100 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof;
b) about 5 mM to about 20 mM histidine buffer;
c) about 6% to about 8% weight/volume (w/v) sucrose;
d) about 0.01% to about 0.10% polysorbate 80; and
e) about 1 mM to about 20 mM L-methionine, or a pharmaceutically acceptable salt thereof,
wherein the anti-human PD-1 antibody or antigen binding fragment thereof comprises three light chain CDRs comprising CDRL1 of SEQ ID NO:1, CDRL2 of SEQ ID NO:2 and CDRL3 of SEQ ID NO:3 and three heavy chain CDRs of CDRH1 of SEQ ID NO:6, CDRH2 of SEQ ID NO:7 and CDRH3 of SEQ ID NO:8.
2. The anti-human PD-1 antibody formulation of claim 1 , wherein the formulation has a pH between 5.0 and 6.0.
3. The anti-human PD-1 antibody formulation of claim 1 , further comprising from about 1% to about 3% w/v L-arginine, or a pharmaceutically acceptable salt thereof.
4. The anti-human PD-1 antibody formulation of claim 1 , comprising:
a) about 100 to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof;
b) 8 mM to about 12 mM histidine buffer;
c) about 5 mM to about 10 mM L-methionine, or a pharmaceutically acceptable salt thereof;
d) about 6% to about 8% w/v sucrose; and
e) 0.01% to about 0.04% w/v polysorbate 80.
5. The anti-human PD-1 antibody formulation of claim 4 , comprising:
a) about 125 to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof;
b) about 10 mM histidine buffer;
c) about 10 mM L-methionine, or a pharmaceutically acceptable salt thereof;
d) about 7% w/v sucrose; and
e) about 0.02% to w/v polysorbate 80.
6. The anti-human PD-1 antibody formulation of claim 5 , wherein the antioxidant is L-methionine HCl.
7. The anti-human PD-1 antibody formulation of claim 5 , further comprising from about 1.25% to about 2.5% w/v L-arginine, or a pharmaceutically acceptable salt thereof.
8. The anti-human PD-1 antibody formulation of claim 1 , wherein the formulation further comprises a metal chelator.
9. The anti-human PD-1 antibody formulation of claim 8 , wherein the metal chelator is diethylenetriaminepentaacetic acid (DTPA), which is present at a concentration of about 10 μM to about 30 μM.
10. The anti-human PD-1 antibody formulation of claim 1 that is a reconstituted solution from a lyophilized formulation.
11. The anti-human PD-1 antibody formulation of claim 1 , wherein the anti-human PD-1 antibody or antigen binding fragment thereof comprises a V L region which comprises the amino acid sequence set forth in SEQ ID NO:4, and a V H region which comprises the amino acid sequence set forth in SEQ ID NO:9.
12. The anti-human PD-1 antibody formulation of claim 1 , wherein the formulation comprises a light chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO:5 and a heavy chain comprising or consisting of a sequence of amino acids as set forth in SEQ ID NO: 10.
13. The anti-human PD-1 antibody formulation of claim 1 , wherein the formulation comprises an anti-human PD-1 antibody that is pembrolizumab.
14. The formulation of claim 13 , wherein the formulation is contained in an injection device.
15. The formulation of claim 13 , wherein the formulation is contained in a glass vial.
16. The anti-human PD-1 antibody formulation of claim 1 , wherein the concentration of the anti-human PD-1 antibody or antigen binding fragment thereof is about 165 to about 170 mg/ml.
17. A method of treating chronic infection in a human patient in need thereof comprising: administering to the human patient an effective amount of an anti-human PD-1 antibody formulation comprising:
a) about 100 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof;
b) about 5 mM to about 20 mM histidine buffer;
c) about 6% to about 8% weight/volume (w/v) sucrose;
d) about 0.01% to about 0.10% polysorbate 80; and
e) about 1 mM to about 20 mM L-methionine, or a pharmaceutically acceptable salt thereof,
wherein the anti-human PD-1 antibody or antigen binding fragment thereof comprises three light chain CDRs comprising CDRL1 of SEQ ID NO:1, CDRL2 of SEQ ID NO:2 and CDRL3 of SEQ ID NO:3 and three heavy chain CDRs of CDRH1 of SEQ ID NO:6, CDRH2 of SEQ ID NO:7 and CDRH3 of SEQ ID NO:8.
18. A method of treating cancer in a human patient in need thereof, the method comprising administering to the human patient an effective amount of an anti-human PD-1 antibody formulation comprising:
a) about 100 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof;
b) about 5 mM to about 20 mM histidine buffer;
c) about 6% to about 8% weight/volume (w/v) sucrose;
d) about 0.01% to about 0.10% polysorbate 80; and
e) about 1 mM to about 20 mM L-methionine, or a pharmaceutically acceptable salt thereof,
wherein the anti-human PD-1 antibody or antigen binding fragment thereof comprises three light chain CDRs comprising CDRL1 of SEQ ID NO:1, CDRL2 of SEQ ID NO:2 and CDRL3 of SEQ ID NO:3 and three heavy chain CDRs of CDRH1 of SEQ ID NO:6, CDRH2 of SEQ ID NO:7 and CDRH3 of SEQ ID NO:8.
19. The method of claim 18 , wherein the anti-human PD-1 antibody formulation is administered by subcutaneous administration.
20. The method of claim 19 , wherein the anti-human PD-1 antibody is pembrolizumab.
21. A method of treating cancer in a human patient in need thereof, the method comprising administering to the human patient an effective amount of an anti-human PD-1 antibody formulation comprising:
a) about 125 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody, or antigen binding fragment thereof;
b) about 10 mM histidine buffer,
c) about 7% w/v sucrose,
d) about 0.02% polysorbate 80,
e) about 10 mM L-methionine, or a pharmaceutically acceptable salt thereof,
f) a pH between 5.0 and 6.0,
wherein the anti-human PD-1 antibody or antigen binding fragment thereof is pembrolizumab,
wherein the formulation is administered by subcutaneous administration.